(Q33695141)

28 July 2017

Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries (English)

1 reference

28 July 2017

0 references

0 references

Cho Naing

1

1 reference

28 July 2017

Kyan Aung

series ordinal

2

1 reference

28 July 2017

Daw-Khin Win

series ordinal

3

1 reference

28 July 2017

Mak Joon Wah

series ordinal

4

1 reference

28 July 2017

language of work or name

1 reference

20 September 2010

1 reference

Transactions of the Royal Society of Tropical Medicine and Hygiene

28 July 2017

1 reference

28 July 2017

104

1 reference

28 July 2017

11

1 reference

28 July 2017

695-705

1 reference

Focus on Plasmodium vivax

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Vivax malaria: neglected and not benign

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Effects of Plasmodium vivax malaria in pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Efficacy of chloroquine in the treatment of Plasmodium vivax malaria in Turkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Therapeutic efficacy of chloroquine plus sulphadoxine/ pyrimethamine compared with monotherapy with either chloroquine or sulphadoxine/pyrimethamine in uncomplicated Plasmodium falciparum malaria in Laos

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Therapeutic responses of Plasmodium vivax and P. falciparum to chloroquine, in an area of western India where P. vivax predominates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

COMPARISON OF CHLOROQUINE, QUINACRINE (ATABRINE), AND QUININE IN THE TREATMENT OF ACUTE ATTACKS OF SPOROZOITE-INDUCED VIV AX MALARIA (CHESSON STRAIN).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Comparative efficacy of chloroquine and sulphadoxine--pyrimethamine in pregnant women and children: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Artemisinin derivatives versus quinine in treating severe malaria in children: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Treatment of malaria in the United States: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of Plasmodium vivax malaria in India.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a randomised non-inferiority trial in eastern Afghanistan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Compliance with 14-day primaquine therapy for radical cure of vivax malaria--a randomized placebo-controlled trial comparing unsupervised with supervised treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Chloroquine sensitivity of Plasmodium vivax in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Therapeutic responses to different antimalarial drugs in vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Efficacy of a 14-day primaquine regimen in preventing relapses in patients with Plasmodium vivax malaria in Mumbai, India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Development of resistance to chloroquine by Plasmodium vivax in Myanmar

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Triangular test applied to the clinical trial of azithromycin against relapses in Plasmodium vivax infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Resistance to therapies for infection by Plasmodium vivax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

A systematic overview of published antimalarial drug trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2010.08.009

10.1016/J.TRSTMH.2010.08.009

7 January 2021

Identifiers

DOI

1 reference

28 July 2017

1 reference